Abstract: Compounds of the formula ##STR1## wherein A, Y, X, B and D are described in the specification are disclosed. The compounds possess activity in treating asthma and other pathologies of the respiratory tract.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are defined in the specification; n is 1 to 3;Y is ##STR2## wherein R.sup.3 is hydrogen, perfluoro alkyl of 1-6 carbon atoms, trifluoromethylalkyl of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; and R.sup.4 is hydrogen or alkyl of 1-6 carbon atoms;with the proviso that when R.sup.1 is ##STR3## then R.sup.2 cannot be ##STR4## wherein X is as defined above; and the pharmaceutically acceptable salts thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart-failure.

Abstract: Substituted heterocycles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I are useful as angiotensin II antagonists. ##STR1## wherein the substituents are as defined in the claims.

Abstract: A photo reactive material, such as a photochromic material, which has the following structure: ##STR1## where the variables, A, R, R', R", R*, R.sup.+, m, and n are defined in claim 1.

Abstract: Photochromic materials which have a structure which includes a spiro-pyrrolidinebenzoxazine structure comprising a pyrrolidine part and a benzoxazine part and the benzoxazine part includes at least one mesomeric electron donating group chosen from amino and alkoxy moieties, the one or more mesomeric electron donating groups being linked to the 6' position via attachment to a conjugated system in which the unsaturated bonds forming the linkage are chosen from --C.dbd.C--, --C.tbd.C--, --C.dbd.N-- and --N.dbd.N--.

Abstract: Photochromic compounds having the following structure II ##STR1## in which R.sup.1 is a group selected from hydrogen, alkyl, alkoxy, amino, aryl or heteroaryl;each R.sup.2 is a group selected from C1 to C10 branched or linear alkyls, carbocylic or heterocyclic, the R.sup.2 groups can be independent or together from part of a carboxylic or heterocyclic ring;R.sup.3 is a group selected from hydrogen, alkyl, alkoxy, alkenyl, alkynyl, imino, azo, amino, carboxy ester, amide, cyano, halogen, trifluoromethyl, nitro, aryl or heteroaryl, R.sup.3 is a fused carbocyclic or heterocyclic moiety;Y is a six membered carbocyclic or heterocyclic ring.X links N as shown to the ring Y to form a fused heterocyclic ring.

Abstract: Disclosed are compounds of formula ##STR1## wherein F represents: ##STR2## or a pharmaceutically acceptable salt. The compounds are useful in treating hyperproliferative skin disease, allergic reactions and inflamation.

Abstract: A charger for a rechargeable alkaline manganese (RAM) battery has a positive contact which engages against the positive terminal of a compatible battery without making electrical contact with the positive terminal protruding nubbin. A rechargeable battery has an insulating jacket which surrounds the battery side wall but which does not overlap the positive terminal. Hence the charger positive contact may engage against the specially adapted battery and electrical contact, but will not make electrical contact with a conventional battery having a partially insulated positive terminal. Alternatively, the battery positive terminal may be insulated within less than 0.040 inches of the battery perimeter and be charged by protruding positive contacts spaced inwardly from the perimeter by approximately the same amount.

Abstract: A pyridylpyrimidine compound of the formula (I) ##STR1## in which A is N and B is CH or A is CH and B is NC is N and D is CH or C is CH and D is N,R.sup.1 is, for example, chiral or achiral alkyl having 1 to 16 carbon atoms,R.sup.2 is, for example, , R.sup.1,X.sup.1, X.sup.2 are F, Cl or CN, andn, m are 0, 1 or 2,are components which are suitable for liquid-crystalline mixtures since they result in LC displays having favorable properties.

Abstract: 2,4-Diaminoquinazoline derivatives as potentiators of chemotherapeutic agents in the treatment of cancer.

Abstract: Methods, compounds and compositions are provided form inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic mycobacterial infections in vivo using indolo[2,1-b]quinazoline-6,12-dione compounds of the formula (I): ##STR1## wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, and may be used alone, or in combination with other anti-Mycobacterium tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, rifabutin, streptomycin and ciprofloxacin, to provide new agents for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDRTB).

Abstract: The compounds of the formula: ##STR1## wherein R.sup.1, Y, A, Z, CyB, R.sup.3, R.sup.4, n and m are described in the specification and claims.and acid addition salts thereof, salts thereof, and hydrates thereof; have inhibitory effect on cGMP-PDE, and additionally on TXA.sub.2 synthetase.

Abstract: Substituted amine derivatives represented by the general formula ##STR1## wherein Q is --C--D--E--F--G--M-- or --N--H--I--J--K--L-- [C, D, E, F, G, H, I, J, K and L are each O, S, a carbonyl group, --CHR.sup.a --, --R.sup.b .dbd. or --NR.sup.c -- (R.sup.a, R.sup.b and R.sup.c are each H or a lower alkyl group), M and N are each an aromatic ring of 5-6 members optionally having a halogen, OH, LN, a lower alkyl group or a lower alkoxy group, provided that L is not O, S, or --NR.sup.c --]; R is a heterocyclic ring of 5-6 members; R.sup.1 is H, a lower alkyl group, a lower haloalkyl group, a lower alkenyl group, a lower alkynyl group or a cycloalkyl group; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are each H, a halogen or a lower alkyl group or two of them denote a single bond; R.sup.8 and R.sup.9 are each F, CF.sub.3 or a lower alkyl group or are a cycloalkane in combination thereof; and R.sup.10 is H, F, CF.sub.3 an acetoxy group, a lower alkyl group or a lower alkoxy group.

Abstract: A battery discharge control circuit is provided with a timer for timing the decision of the state of a battery loaded into a battery discharger between a discharged state and a nondischarged state so that the state of the battery is decided a predetermined time after the battery has been loaded into the battery discharger. The control circuit prevents the battery discharger from discharging an undischarged battery due to noise generated by chattering contact between the battery and the battery discharger in loading the battery into the battery discharger or due to the variation of the detected value of the terminal voltage of the battery caused by the influence of the self-healing characteristic and temperature characteristic of the battery. The control circuit also prevents the battery discharger from again discharging a discharged battery.

Abstract: Pharmaceutical or cosmetic composition intended to be used, by topical application, for retarding hair loss and for inducing or stimulating hair growth, containing at least one compound of formula: ##STR1## where: R.sub.1 denotes H or C.sub.1 -C.sub.8 alkyl;R.sub.2 denotes C.sub.1 -C.sub.8 alkyl or NHR.sub.3, where R.sub.3 denotes H or --COOR.sub.4, where R.sub.4 denotes C.sub.1 -C.sub.4 alkyl;X denotes ##STR2## --OR.sub.9 or --SR.sub.10 ; R.sub.5 and R.sub.6 denote H, optionally substituted C.sub.1 -C.sub.12 alkyl, or C.sub.2 -C.sub.12 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, aralkyl or aryl, or form, with N, a saturated or unsaturated heterocycle;R.sub.9 denotes optionally substituted C.sub.1 -C.sub.12 alkyl, or C.sub.2 -C.sub.12 alkenyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.7 -C.sub.12 aralkyl or phenyl, which may optionally be substituted;R.sub.10 is identical to R.sub.9 ; andY denotes O or OSO.sub.3.sup..crclbar. ;as well as its cosmetically or pharmaceutically acceptable acid addition salts.

Abstract: Novel substituted heterocyclic formamidines are useful as ultraviolet light absorbers, the formamidines having the formula ##STR1## wherein: Ar represents a 2-thiazolyl, 2-pyridyl, 2- 4,6-dimethyl) pyrmidyl or a 4-(2-methyl)quinolyl group, and,R represents a phenyl group or an alkyl group of from one to eight carbon atoms.

Abstract: The compounds of the formula: ##STR1## wherein R.sup.1, Y, A, R.sup.4, n, Z, CyB, R.sup.3, and m are defined in the specification.

Abstract: A compound represented by the general formula: ##STR1## wherein Y represents a nitrogen atom or C--G (G represents a carboxyl group which may be esterified); ring R is a nitrogen-containing unsaturated heterocyclic group which may be substituted or unsubstituted; each of rings A and B may have a substituent; n represents an integer from 1 to 4; k represents the integer 0 or 1, or a salt thereof, which serves well as an anti-inflammatory agent, particularly a therapeutic agent for arthritis.

Abstract: 1,3-Oxazin-4-one derivatives represented by general formula (I) ##STR1## wherein R.sup.1 is a lower alkyl group, a lower alkenyl group, an aryl group which may be substituted, or an aralkyl group which may be substituted;R.sup.2 is a hydrogen atom or a lower alkyl group;R.sup.3 is a lower alkyl group, an aryl group which may be substituted, or an aralkyl group which may be substituted; andR.sup.4 and R.sup.5, independently, each is a lower alkyl group, or R.sup.4 and R.sup.5, taken together with the carbon atom to which they are bonded, combine to form a 3- to 8-membered carbocyclic group which may have a branch of a lower alkyl group. These compounds have broad herbicidal spectra and potent herbicidal activities and in addition high safety to useful crops, so that they are useful as herbicides.

Abstract: Tricyclic nitrogen containing compounds, having central nervous system activity of the following structural formula: ##STR1## and pharmaceutically acceptable salts thereof wherein R.sub.1, R.sub.2, and R.sub.3 are independently hydrogen, C.sub.1-6 alkyl, alkenyl, or alkynyl, C.sub.3-10 cycloalkyl, or R.sub.1 and R.sub.2 are joined to form a C.sub.3-7 cyclic amine which can contain additional heteroatoms; X is hydrogen, C.sub.1-6 alkyl, halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl; A is SO.sub.2, N, CH, CH.sub.2, CHCH.sub.3, C=O, C=S, C-SCH.sub.3, C=NH, C-NH.sub.2, C-NHCH.sub.3, CNHCOOCH.sub.3, or C-NHCN. B is CH.sub.2, CH, C=O, N, NH or N-CH.sub.3 ; n is 0 or 1; and D is CH, CH.sub.2, C=O, 0, N, NH or N-CH.sub.3. These new compounds are suitable for treating schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure in animal or human hosts.